Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study

BACKGROUND: Apatinib, a selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR 2), has exhibited modest antitumor efficacy in hepatocellular carcinoma (HCC). We aimed to evaluate the effectiveness and tolerability of apatinib versus sorafenib in patients with advanced HCC. METHO...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ann Transl Med
Päätekijät: He, Wei, Liao, Leen, Hu, Dandan, Li, Binkui, Wang, Chenwei, Qiu, Jiliang, Liao, Yadi, Liu, Wenwu, Yang, Zhiwen, Zhang, Yuanping, Yuan, Yichuan, Li, Kai, Yuan, Yunfei, Zheng, Yun
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AME Publishing Company 2020
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7475472/
https://ncbi.nlm.nih.gov/pubmed/32953800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-20-5298
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia